Continuous processing is an alternative manufacturing method involving flow reactors that allow chemical reactions to run on a smaller scale over and over again until the entire volume of API is produced. This maximizes throughput, increases product quality and reproducibility, and has significantly lower labor requirements since most of these systems are highly automated.
This is primarily due to legacy capital investments in batch manufacturing at pharmaceutical manufacturing operations, as well as the regulatory barriers associated with implementing a new manufacturing platform. In particular, pharmaceutical companies have been unwilling to take the business and regulatory risk associated with transitioning to a different infrastructure and process. Phlow will take on these challenges and secure the nation’s supply of its most essential medicines.